|
1
|
Huang S, Yang J, Shen N, Xu Q and Zhao Q:
Artificial intelligence in lung cancer diagnosis and prognosis:
Current application and future perspective. Semin Cancer Biol.
89:30–37. 2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lee E and Kazerooni EA: Lung cancer
screening. Semin Respir Crit Care Med. 43:839–850. 2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cho JH: Immunotherapy for non-small-cell
lung cancer: Current status and future obstacles. Immune Netw.
17:378–391. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chen Y, Mathy NW and Lu H: The role of
VEGF in the diagnosis and treatment of malignant pleural effusion
in patients with nonsmall cell lung cancer (review). Mol Med Rep.
17:8019–8030. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ferreiro L, Suárez-Antelo J,
Álvarez-Dobaño JM, Toubes ME, Riveiro V and Valdés L: Malignant
pleural effusion: Diagnosis and management. Can Respir J.
2020(2950751)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Russo A, Lopes AR, McCusker MG, Garrigues
SG, Ricciardi GR, Arensmeyer KE, Scilla KA, Mehra R and Rolfo C:
New targets in lung cancer (excluding EGFR, ALK, ROS1). Curr Oncol
Rep. 22(48)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mao L, Zhao W, Li X, Zhang S, Zhou C, Zhou
D, Ou X, Xu Y, Tang Y, Ou X, et al: Mutation spectrum of
EGFR from 21,324 Chinese patients with non-small cell lung
cancer (NSCLC) successfully tested by multiple methods in a
CAP-accredited laboratory. Pathol Oncol Res.
27(602726)2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Mohammed A, Hochfeld U, Hong S, Hosseini
DK, Kim K and Omidvari K: Thoracentesis techniques: A literature
review. Medicine (Baltimore). 103(e36850)2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Porcel JM: Diagnosis and characterization
of malignant effusions through pleural fluid cytological
examination. Curr Opin Pulm Med. 25:362–368. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ramalingam SS, Vansteenkiste J, Planchard
D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y,
Chewaskulyong B, et al: Overall survival with osimertinib in
untreated, EGFR-mutated advanced NSCLC. N Engl J Med.
382:41–50. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Su C: Emerging insights to lung cancer
drug resistance. Cancer Drug Resist. 5:534–540. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wu YL, Saijo N, Thongprasert S, Yang JC,
Han B, Margono B, Chewaskulyong B, Sunpaweravong P, Ohe Y, Ichinose
Y, et al: Efficacy according to blind independent central review:
Post-hoc analyses from the phase III, randomized, multicenter,
IPASS study of first-line gefitinib versus carboplatin/paclitaxel
in Asian patients with EGFR mutation-positive advanced NSCLC. Lung
Cancer. 104:119–125. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Shi Y, Zhang L, Liu X, Zhou C, Zhang L,
Zhang S, Wang D, Li Q, Qin S, Hu C, et al: Icotinib versus
gefitinib in previously treated advanced non-small-cell lung cancer
(ICOGEN): A randomised, double-blind phase 3 non-inferiority trial.
Lancet Oncol. 14:953–961. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hu X, Zhang L, Shi Y, Zhou C, Liu X, Wang
D, Song Y, Li Q, Feng J, Qin S, et al: The efficacy and safety of
Icotinib in patients with advanced non-small cell lung cancer
previously treated with chemotherapy: A single-arm, multi-center,
prospective study. PLoS One. 10(e0142500)2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M,
et al: NCCN guidelines® insights: Non-small cell lung
cancer, version 2.2023. J Natl Compr Canc Netw. 21:340–350.
2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wang JL, Fu YD, Gao YH, Li XP, Xiong Q, Li
R, Hou B, Huang RS, Wang JF, Zhang JK, et al: Unique
characteristics of G719X and S768I compound double mutations of
epidermal growth factor receptor (EGFR) gene in lung cancer of
coal-producing areas of East Yunnan in Southwestern China. Genes
Environ. 44(17)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Batra U, Biswas B, Prabhash K and Krishna
MV: Differential clinicopathological features, treatments and
outcomes in patients with exon 19 deletion and exon 21 L858R EGFR
mutation-positive adenocarcinoma non-small-cell lung cancer. BMJ
Open Respir Res. 10(e001492)2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kutsuzawa N, Takahashi F, Tomomatsu K,
Obayashi S, Takeuchi T, Takihara T, Hayama N, Oguma T, Aoki T and
Asano K: Successful treatment of a patient with lung adenocarcinoma
harboring compound EGFR gene mutations, G719X and S768I, with
afatinib. Tokai J Exp Clin Med. 45:113–116. 2020.PubMed/NCBI
|
|
20
|
Suda K, Mitsudomi T, Shintani Y, Okami J,
Ito H, Ohtsuka T, Toyooka S, Mori T, Watanabe SI, Asamura H, et al:
Clinical impacts of EGFR mutation status: Analysis of 5780
surgically resected lung cancer cases. Ann Thorac Surg.
111:269–276. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yao Y, Peng M, Shen Q, Hu Q, Gong H, Li Q,
Zheng Z, Xu B, Li Y and Dong Y: Detecting EGFR mutations and
ALK/ROS1 rearrangements in non-small cell lung cancer using
malignant pleural effusion samples. Thorac Cancer. 10:193–202.
2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wang H, Zhang W, Wang K and Li X:
Correlation between EML4-ALK, EGFR and clinicopathological features
based on IASLC/ATS/ERS classification of lung adenocarcinoma.
Medicine (Baltimore). 97(e11116)2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang T, Zhang Y, Liu B, Hu M, Zhou N and
Zhi X: Associations between epidermal growth factor receptor
mutations and histological subtypes of lung adenocarcinoma
according to the IASLC/ATS/ERS classification in Chinese patients.
Thorac Cancer. 8:600–605. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Li D, Ding L, Ran W, Huang Y, Li G, Wang
C, Xiao Y, Wang X, Lin D and Xing X: Status of 10 targeted genes of
non-small cell lung cancer in eastern China: A study of 884
patients based on NGS in a single institution. Thorac Cancer.
11:2580–2589. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
He C, Wei C, Wen J, Chen S, Chen L, Wu Y,
Shen Y, Bai H, Zhang Y, Chen X and Li X: Comprehensive analysis of
NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases
of NSCLC patients. J Cancer Res Clin Oncol. 148:321–330.
2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Xu T, Kang X, You X, Dai L, Tian D, Yan W,
Yang Y, Xiong H, Liang Z, Zhao GQ, et al: Cross-platform comparison
of four leading technologies for detecting EGFR mutations in
circulating tumor DNA from non-small cell lung carcinoma patient
plasma. Theranostics. 7:1437–1446. 2017.PubMed/NCBI View Article : Google Scholar
|
